SG11202008641WA - Crystalline forms of an sgc stimulator - Google Patents
Crystalline forms of an sgc stimulatorInfo
- Publication number
- SG11202008641WA SG11202008641WA SG11202008641WA SG11202008641WA SG11202008641WA SG 11202008641W A SG11202008641W A SG 11202008641WA SG 11202008641W A SG11202008641W A SG 11202008641WA SG 11202008641W A SG11202008641W A SG 11202008641WA SG 11202008641W A SG11202008641W A SG 11202008641WA
- Authority
- SG
- Singapore
- Prior art keywords
- crystalline forms
- sgc stimulator
- sgc
- stimulator
- crystalline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862639846P | 2018-03-07 | 2018-03-07 | |
| PCT/US2019/021080 WO2019173551A1 (en) | 2018-03-07 | 2019-03-07 | Crystalline forms of an sgc stimulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202008641WA true SG11202008641WA (en) | 2020-10-29 |
Family
ID=65818696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202008641WA SG11202008641WA (en) | 2018-03-07 | 2019-03-07 | Crystalline forms of an sgc stimulator |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11466015B2 (es) |
| EP (1) | EP3762389B1 (es) |
| JP (1) | JP7423539B2 (es) |
| KR (1) | KR20200128708A (es) |
| CN (1) | CN111836812A (es) |
| AU (1) | AU2019231724B2 (es) |
| BR (1) | BR112020018212A2 (es) |
| CA (1) | CA3092683A1 (es) |
| CL (5) | CL2020002284A1 (es) |
| CO (1) | CO2020012493A2 (es) |
| CR (1) | CR20200458A (es) |
| EA (1) | EA202092109A1 (es) |
| IL (1) | IL276853A (es) |
| MA (1) | MA54638A (es) |
| MX (5) | MX2020009183A (es) |
| PE (1) | PE20210124A1 (es) |
| PH (1) | PH12020551394A1 (es) |
| SG (1) | SG11202008641WA (es) |
| TW (1) | TWI823903B (es) |
| WO (1) | WO2019173551A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202100092QA (en) * | 2018-07-11 | 2021-02-25 | Cyclerion Therapeutics Inc | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS |
| WO2021195403A1 (en) * | 2020-03-26 | 2021-09-30 | Cyclerion Therapeutics, Inc. | Deuterated sgc stimulators |
| CN118221649A (zh) * | 2022-12-21 | 2024-06-21 | 广东东阳光药业股份有限公司 | 氟取代的吲唑化合物的晶型及其用途 |
| CN118221651A (zh) * | 2022-12-21 | 2024-06-21 | 广东东阳光药业股份有限公司 | 氟取代的吲唑化合物的晶型及其用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2928079B2 (ja) | 1994-02-14 | 1999-07-28 | 永信薬品工業股▲ふん▼有限公司 | １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途 |
| DE19744026A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| EP1614678B1 (en) | 1998-07-08 | 2014-01-01 | Sanofi-Aventis Deutschland GmbH | Sulfur substituted sulfonylaminocarboxylic acid N-heteroarylamides, their preparation, their use and pharmaceutical preparations comprising them |
| DE19830430A1 (de) | 1998-07-08 | 2000-01-13 | Hoechst Marion Roussel De Gmbh | Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| GB9824310D0 (en) | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
| DE19942809A1 (de) | 1999-09-08 | 2001-03-15 | Bayer Ag | Verfahren zur Herstellung substituierter Pyrimidinderivate |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10216145A1 (de) | 2002-04-12 | 2003-10-23 | Bayer Ag | Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| EA201070339A1 (ru) | 2007-09-06 | 2010-10-29 | Мерк Шарп Энд Домэ Корп. | Активаторы растворимой гуанилатциклазы |
| EP2244575B1 (en) | 2008-01-24 | 2013-07-17 | Merck Sharp & Dohme Corp. | Angiotensin ii receptor antagonists |
| AU2009322836B2 (en) | 2008-11-25 | 2013-04-04 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| EP2401265B1 (en) | 2009-02-26 | 2016-09-14 | Merck Sharp & Dohme Corp. | Derivatives of 1-pyri(mid)in-2-yl-pyrazole-4-carboxylic acid which are useful for therapy or prophylaxis of cardiovascular diseases |
| WO2011119518A1 (en) | 2010-03-25 | 2011-09-29 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| PE20130222A1 (es) | 2010-05-27 | 2013-03-14 | Merck Sharp & Dohme | Activadores de guanilato ciclasa soluble |
| WO2012058132A1 (en) | 2010-10-28 | 2012-05-03 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| CN104327107A (zh) * | 2013-10-17 | 2015-02-04 | 广东东阳光药业有限公司 | 一种氟喹诺酮类抗菌药物的制备方法 |
| EP3152214B1 (en) * | 2014-06-04 | 2020-01-29 | Merck Sharp & Dohme Corp. | Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators |
| CA2969265A1 (en) * | 2014-12-02 | 2016-06-09 | Bayer Pharma Aktiengesellschaft | Substituted pyrazolo[1,5-a]pyridines and imidazo[1,2-a]pyrazines and their use |
| CR20190101A (es) * | 2016-09-02 | 2019-07-04 | Ironwood Pharmaceuticals Inc | Estimuladores de sgc |
-
2019
- 2019-03-07 CA CA3092683A patent/CA3092683A1/en active Pending
- 2019-03-07 MX MX2020009183A patent/MX2020009183A/es unknown
- 2019-03-07 MX MX2023004857A patent/MX2023004857A/es unknown
- 2019-03-07 MX MX2023004858A patent/MX2023004858A/es unknown
- 2019-03-07 MX MX2023004855A patent/MX2023004855A/es unknown
- 2019-03-07 AU AU2019231724A patent/AU2019231724B2/en active Active
- 2019-03-07 EA EA202092109A patent/EA202092109A1/ru unknown
- 2019-03-07 CR CR20200458A patent/CR20200458A/es unknown
- 2019-03-07 SG SG11202008641WA patent/SG11202008641WA/en unknown
- 2019-03-07 EP EP19712427.4A patent/EP3762389B1/en active Active
- 2019-03-07 MA MA054638A patent/MA54638A/fr unknown
- 2019-03-07 TW TW108107664A patent/TWI823903B/zh active
- 2019-03-07 JP JP2020546378A patent/JP7423539B2/ja active Active
- 2019-03-07 CN CN201980017657.XA patent/CN111836812A/zh active Pending
- 2019-03-07 KR KR1020207028170A patent/KR20200128708A/ko not_active Application Discontinuation
- 2019-03-07 WO PCT/US2019/021080 patent/WO2019173551A1/en unknown
- 2019-03-07 MX MX2023004856A patent/MX2023004856A/es unknown
- 2019-03-07 US US16/976,430 patent/US11466015B2/en active Active
- 2019-03-07 BR BR112020018212-5A patent/BR112020018212A2/pt unknown
- 2019-03-07 PE PE2020001347A patent/PE20210124A1/es unknown
-
2020
- 2020-08-20 IL IL276853A patent/IL276853A/en unknown
- 2020-09-03 CL CL2020002284A patent/CL2020002284A1/es unknown
- 2020-09-05 PH PH12020551394A patent/PH12020551394A1/en unknown
- 2020-10-06 CO CONC2020/0012493A patent/CO2020012493A2/es unknown
-
2021
- 2021-02-04 CL CL2021000301A patent/CL2021000301A1/es unknown
- 2021-12-28 CL CL2021003536A patent/CL2021003536A1/es unknown
- 2021-12-28 CL CL2021003531A patent/CL2021003531A1/es unknown
- 2021-12-28 CL CL2021003530A patent/CL2021003530A1/es unknown
-
2022
- 2022-09-28 US US17/954,713 patent/US20230095799A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202001071VA (en) | Multi-factor control of ear stimulation | |
| IL268852A (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitantane | |
| IL276644A (en) | crystalline forms | |
| IL276853A (en) | Aggregate forms of SGC stimulator | |
| IL265951A (en) | Multifactorial control of ear stimulation | |
| IL263996A (en) | Solid configurations of sgc promoter | |
| IL275415A (en) | sGC fans | |
| PT3577125T (pt) | Formas cristalinas de tenofovir alafenamida | |
| IL269626A (en) | Crystalline salt forms of BOC-D-ARG-DMT-LYS-(BOC)-PHE-NH2 | |
| SG11202100092QA (en) | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS | |
| IL266372A (en) | running sgc | |
| IL276592A (en) | History of Subtirum | |
| IL263993A (en) | Phosphorylated prodrugs of SGC stimulators | |
| EP3894768C0 (en) | METHOD FOR CRYOHARDENING | |
| PL3529236T3 (pl) | Krystaliczne formy erawacykliny | |
| PL3532457T3 (pl) | Postacie krystaliczne hydroksynorketaminy | |
| IL269073A (en) | Crystalline forms of obeticholic acid | |
| SI3749673T1 (sl) | Kristalinična oblika biktegravir natrija | |
| EP3793980A4 (en) | CRYSTALLINE FORM OF S-APOMORPHINE | |
| IL269792B (en) | Crystalline forms of (s)–apoxolner | |
| IL270961A (en) | Crystalline form of N-butyldeoxygalactonogirimycin | |
| SG11202100267TA (en) | Solid forms of an azolopyrimidine compound | |
| SG11202108905UA (en) | Crystalline form of an avibactam derivative | |
| GB201912411D0 (en) | Crystalline forms of ivosidenib | |
| IL278054A (en) | The crystalline forms of a compound |